Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VNRX-7145 in healthy volunteers
NCT04243863Phase 1Completed
- Sponsor
- Basilea Pharmaceutica
- Start
- Jan 2020
- Primary completion
- Apr 2021
- Modality
- Reversible Covalent Inhibitors
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial comparing VNRX-7145 with Placebo (2 arms). Primary endpoint: Adverse Events at 17 days. Started Jan 2020; status: completed.
02
Drugs
ledaborbactam etzadroxil
Beyond the preview
Go deeper on NCT04243863.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04243863.